Macquarie Group
MRNA icon

Macquarie Group’s Moderna MRNA Stock Holding History

Macquarie Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Sell
3,787
-4,218
-53% -$218K ﹤0.01% 770
2026
Q1 		$407K Sell
8,005
-6,416
-44% -$299K ﹤0.01% 715
2025
Q4 		$425K Sell
14,421
-13,653
-49% -$371K ﹤0.01% 752
2025
Q3 		$726K Sell
28,074
-29,612
-51% -$826K ﹤0.01% 1369
2025
Q2 		$1.59M Sell
57,686
-25,741
-31% -$678K ﹤0.01% 1285
2025
Q1 		$2.37M Buy
83,427
+33,865
+68% +$1.2M ﹤0.01% 1171
2024
Q4 		$1.52M Buy
49,562
+15,884
+47% +$759K ﹤0.01% 1274
2024
Q3 		$2.25M Buy
33,678
+970
+3% +$89.1K ﹤0.01% 1193
2024
Q2 		$3.88M Sell
32,708
-10,027
-23% -$1.27M ﹤0.01% 1034
2024
Q1 		$4.55M Buy
42,735
+4,665
+12% +$470K 0.01% 987
2023
Q4 		$3.79M Buy
38,070
+4,648
+14% +$391K ﹤0.01% 1032
2023
Q3 		$3.45M Sell
33,422
-848
-2% -$94.6K ﹤0.01% 1016
2023
Q2 		$4.16M Sell
34,270
-575
-2% -$76.7K ﹤0.01% 969
2023
Q1 		$5.35M Sell
34,845
-126
-0.4% -$20.8K 0.01% 924
2022
Q4 		$6.28M Buy
34,971
+17,664
+102% +$2.89M 0.01% 937
2022
Q3 		$2.05M Sell
17,307
-141
-0.8% -$21.4K ﹤0.01% 1221
2022
Q2 		$2.49M Sell
17,448
-378,931
-96% -$54.2M ﹤0.01% 1222
2022
Q1 		$68.3M Sell
396,379
-2,161
-0.5% -$364K 0.05% 417
2021
Q4 		$101M Sell
398,540
-413,013
-51% -$121M 0.08% 303
2021
Q3 		$312M Sell
811,553
-702,982
-46% -$259M 0.27% 77
2021
Q2 		$356M Buy
1,514,535
+1,509,612
+30,664% +$270M 0.29% 75
2021
Q1 		$645K Buy
4,923
+810
+20% +$117K ﹤0.01% 1487
2020
Q4 		$430K Buy
4,113
+1,333
+48% +$135K ﹤0.01% 1477
2020
Q3 		$197K Buy
2,780
+116
+4% +$8.09K ﹤0.01% 1611
2020
Q2 		$171K Buy
+2,664
New +$146K ﹤0.01% 1597

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Macquarie Group's MRNA Position: Q2 2026 in Review

Macquarie Group reduced its Moderna (MRNA) stake by 53% in Q2 2026, selling an estimated $218K and leaving 3,787 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #770.

Macquarie Group first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $356M in Q2 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Macquarie Group held 3,787 shares of Moderna worth $265K as of Q2 2026.
  • Macquarie Group sold 4,218 Moderna shares in Q2 2026, an estimated $218K.
  • Moderna made up ﹤0.01% of Macquarie Group's portfolio in Q2 2026, its #770 holding.
  • Macquarie Group first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Macquarie Group's Moderna position peaked at $356M in Q2 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.